Table 1.
Micellar formulations being currently tested in clinical trials
| Polymeric micelle | Block copolymer | Drug | Indication | Clinical phase |
|---|---|---|---|---|
| NK012 | PEG-PGlu(SN-38) | SN-38 | Breast cancer | II |
| NK105 | PEG-P(aspartate) | Paclitaxel | Advanced stomach cancer | II |
| SP1049C | Pluronic L61 and F127 | Doxorubicin | Adenocarcinoma of esophagus, gastroesophageal junction and stomach | III |
| NC-6004 | PEG-PGlu(cisplatin) | Cisplatin | Solid tumors | I/II |
| Genexol-PM | PEG-P(D,L-lactide) | Paclitaxel | Breast cancer | IV |
| Genexol-PM | PEG-P(D,L-lactide) | Paclitaxel | Pancreatic cancer | II |
| Genexol-PM | PEG-P(D,L-lactide) | Paclitaxel | Non-small-cell lung cancer in combination with carboplatin | II |
| Genexol-PM | PEG-P(D,L-lactide) | Paclitaxel | Pancreatic cancer in combination with gemcitabine | I/II |
| Genexol-PM | PEG-P(D,L-lactide) | Paclitaxel | Ovarian cancer in combination with carboplatin | I/II |
Abbreviations: PEG, polyethylene glycol; SN38, 7-Ethyl-10-hydroxy-camptothecin.